
CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:



(I);

wherein:

ring A is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

ring B is aryl or heteroaryl;

ring C is aryl or heteroaryl;

R^a, independently for each occurrence, is selected from the group consisting of halogen, cyano, hydroxy, $-NH_2$, -NH(Ac), -NH(alkyl), $-N(alkyl)_2$, -NHC(O)(alkyl), $-CH_2NHC(O)(alkyl)$, $-C(O)NH_2$, -C(O)(alkyl), optionally substituted aryl, optionally substituted heteroaryl, cycloalkyl, alkoxy, alkyl, (cycloalkyl)alkyl, hydroxyalkyl, aminoalkyl, and haloalkyl;

R^b, independently for each occurrence, is selected from the group consisting of halogen, cyano, $-NR^jR^k$, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)haloalkyl, hydroxy(cycloalkyl)alkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, -alkylene-NR^jR^k, tosyl, $-SO_2(alkyl)$, $-SO_2(cycloalkyl)$, -CO(alkyl), -CO(cycloalkyl), -CONH(alkyl), $-CON(alkyl)_2$, and -CONH(cycloalkyl);

R^c, independently for each occurrence, is selected from the group consisting of halogen, -OH, $-NR^jR^k$, alkoxy, and alkyl;

R^1 is selected from the group consisting of $-NH_2$, $-CH_2COOH$, -CH(NH(CO)(alkyl))COOH, -CH(NH(CO)(arylalkyl))COOH,

-CH(NH(CO)(cycloalkyl))COOH, -CH(NH(CO)(aryl substituted cycloalkyl))COOH, -CO(NH)CH_2aryl, -CO(NH)CH_2heteroaryl, -CO(NH)aryl, and -CO(NH)heteroaryl;

n is 0, 1, or 2;

m is 0, 1, or 2;

p is 0, 1, or 2;

J is –C(O)–, –NH–, –CH_2–, –O–, –S–, –S(O)–, –SO_2–, –N(alkyl)–, or –CH(alkyl)–;

K is –C(O)–, –NH–, –O–, –CH_2–, –S–, –S(O)–, –SO_2–, –N(alkyl)–, or –CH(alkyl)–;

wherein at least one of J and K is –C(O)–, –CH_2–, or –CH(alkyl)–;

L is selected from the group consisting of a bond, –CH_2–, –CH_2CH_2–, –CHR^2–, –CF_2–, –CFR^2–, –C(O)–, –C(=NR^L)–, and –C(=CHR^L)–;

wherein R^L is H or alkyl;

or wherein R^L and an occurrence of R^c taken together with the intervening atoms form a substituted or unsubstituted heteroaryl ring;

R^2 is alkyl, hydroxyalkyl, or haloalkyl;


R^j and R^k are each independently selected from the group consisting of H, alkyl, aminoalkyl, (heterocycloalkyl)alkyl, and heterocycloalkyl;

U is N or CR^3;

R^3 is H, halogen, alkyl, alkoxy, or haloalkyl; and

V is N or CH.

2. The compound of claim 1, having the structure of formula (Ia):



(Ia);

wherein:

W is N, CH, or CR^c;


X is N, CH, or CR^c;

Y is N, CH, or CR^c; and

Z is N, CH, or CR^c.

3. The compound of claim 1 or 2, wherein ring A is phenyl, thiophenyl, or pyridinyl.

4. The compound of claim 2 or 3, having the structure of formula (Ib):



(Ib).

5. The compound of any one of claims 1-4, wherein p is 1.

6. The compound of claim 5, wherein R^a is alkyl, cycloalkyl, or halogen.

7. The compound of any one of claims 1-4, wherein p is 0.

8. The compound of any one of claims 1-7, wherein R^1 is $-CH_2COOH$.


9. The compound of any one of claims 1-8, wherein –J–K– is selected from the group consisting of –C(O)-NH–, –NH-C(O)–, and $–CH_2O–$.

10. The compound of any one of claims 1-9, wherein –J–K– is $–CH_2O–$.

11. The compound of any one of claims 1-10, wherein U is CH.


12. The compound of any one of claims 1-11, wherein V is CH.

13. The compound of any one of claims 2-12, having the structure of formula (Ic):




(Ic).

14. The compound of any one of claims 2-10, having the structure of formula (Id):




(Id).

15. The compound of any one of claims 2-10, having the structure of formula (Ie):



(Ie).

16. The compound of any one of claims 2-10, having the structure of formula (If):



(If).

17. The compound of any one of claims 1-16, wherein m is 0.

18. The compound of any one of claims 1-16, wherein m is 1.

19. The compound of claim 18, wherein R^b is selected from the group consisting of alkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, halogen, and (cycloalkyl)alkyl.

20. The compound of any one of claims 1-16, wherein m is 2.

21. The compound of claim 20, wherein each R^b is alkyl.

22. The compound of any one of claims 2-21, wherein each of W, X, Y, and Z is CH.

23. The compound of any one of claims 2-21, wherein at least one of W, X, Y, and Z is CR^c.

24. The compound of claim 23, wherein Z is CR^c.

25. The compound of claim 23 or 24, wherein Y is CR^c.

26. The compound of any one of claims 23-25, wherein R^c is halogen, e.g., fluoride.

27. The compound of any one of claims 2-21 and 23, wherein at least one of W, X, Y, and Z is N.

28. The compound of claim 27, wherein Z is N.

29. The compound of claim 27, wherein Y is N.

30. The compound of any one of claims 1-29, wherein L is $–CH_2–$.







31. The compound of any one of claims 1-30 or a pharmaceutically acceptable salt thereof, wherein ring B is heteroaryl.











32. The compound of claim 31 or a pharmaceutically acceptable salt thereof, wherein ring B is furyl, oxazolyl, isoxazolyl, thiophenyl, pyrrolyl, pyrazolyl, or imidazolyl.











33. The compound of claim 32 or a pharmaceutically acceptable salt thereof, wherein ring B is furyl.











34. The compound of claim 32 or a pharmaceutically acceptable salt thereof, wherein ring B is pyrrolyl.











35. The compound of claim 1, selected from the following table:











	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	











	
	
	
	
	












	
	
	
	
	











	
	
	
	
	










	
	
	
	
	






	
	
	
	
	


	
	
	
	
	


	
	
	
	
	


	
	
	


.


36. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:




,


,



,


,


, and



.

37. The compound of claim 36, or a pharmaceutically acceptable salt thereof, having the following formula:




.

38. The compound of claim 36, or a pharmaceutically acceptable salt thereof, having the following formula:




.

39. The compound of claim 36, or a pharmaceutically acceptable salt thereof, having the following formula:




.

40. The compound of claim 36, or a pharmaceutically acceptable salt thereof, having the following formula:




.

41. The compound of claim 36, or a pharmaceutically acceptable salt thereof, having the following formula:




.

42. The compound of claim 36, or a pharmaceutically acceptable salt thereof, having the following formula:



.

43. A compound of formula (II), or a pharmaceutically acceptable salt thereof:



(II);

wherein:

ring  is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;

R^a, independently for each occurrence, is selected from the group consisting of halogen, cyano, hydroxy, $-NH_2$, -NH(Ac), -NH(alkyl), $-N(alkyl)_2$, $-NHC(O)(alkyl)$, $-CH_2NHC(O)(alkyl)$, $-C(O)NH_2$, -C(O)(alkyl), optionally substituted aryl, optionally substituted heteroaryl, cycloalkyl, alkoxy, alkyl, (cycloalkyl)alkyl, hydroxyalkyl, aminoalkyl, and haloalkyl;

T^1 is N, CH, NR^{T1}, or CR^{T1};

T^2 is NR^{T2} or CR^{T2};

T^3 is N, CH, NR^{T3}, or CR^{T3};

wherein:

(a) T^1 is CR^{T1} or NR^{T1}, wherein R^{T1} and R^{T2}, taken together with the intervening atoms, form an optionally substituted cycloalkyl, aryl, or heteroaryl ring; and T^3 is N or CH; or

(b) T^3 is CR^{T3} or NR^{T3}; wherein R^{T3} and R^{T2}, taken together with the intervening atoms, form an optionally substituted heteroaryl ring; and

T^1 is N or CH; and

at least one of (a) T^2 is NR^{T2}, (b) T^3 is NR^{T3}, or (c) T^1 is NR^{T1};

R^1 is selected from the group consisting of $-NH_2$, $-CH_2COOH$,

-CH(NH(CO)(alkyl))COOH, -CH(NH(CO)(cycloalkyl))COOH,

$-$ CO(NH)CH_2aryl, -CO(NH)CH_2heteroaryl, -CO(NH)aryl, and

-CO(NH)heteroaryl;

p is 0, 1, or 2;

J is –C(O)–, –NH–, $–CH_2–$, –O–, –S–, –S(O)–, $–SO_2–$, –N(alkyl)–, or –CH(alkyl)–;

K is –C(O)–, –NH–, –O–, $–CH_2–$, –S–, –S(O)–, $–SO_2–$, –N(alkyl)–, or –CH(alkyl)–;

wherein at least one of J and K is –C(O)–, $–CH_2–$, or –CH(alkyl)–;

W is N, CH, or CR^c;

X is N, CH, or CR^c;

Y is N, CH, or CR^c;

Z is N, CH, or CR^c;

R^c, independently for each occurrence, is selected from the group consisting of halogen, -OH, $-NR^jR^k$, alkoxy, and alkyl;

L is selected from the group consisting of a bond, $–CH_2–$, $–CH_2CH_2–$, $–CHR^2–$, $–CF_2–$, $–CFR^2–$, –C(O)–, $–C(=NR^L)–$, and $–C(=CHR^L)–$;

wherein R^L is H or alkyl;


or wherein R^L and an occurrence of R^c taken together with the intervening atoms form a substituted or unsubstituted heteroaryl ring;

R^2 is alkyl, hydroxyalkyl, or haloalkyl;

V is N or CH.

44. The compound of claim 43, wherein ring  is phenyl, thiophenyl, furyl, pyrazole, or pyridinyl.

45. The compound of claim 43 or 44, having the structure of formula (IIa):



(IIa).

46. The compound of any one of claims 43-45, wherein p is 0.

47. The compound of any one of claims 43-46, wherein R^1 is -CH_2COOH.

48. The compound of any one of claims 43-47, wherein –J–K– is selected from the group consisting of –C(O)-NH–, –NH-C(O)–, and –CH_2O–.

49. The compound of any one of claims 43-48, wherein each of W, X, Y, and Z is CH.

50. The compound of any one of claims 43-48, wherein at least one of W, X, Y, and Z is CR^c, e.g., Z is CR^c.












51. The compound of claim 50, wherein R^c is halogen, e.g., fluoride.









52. The compound of any one of claims 43-51, wherein L is –CH_2–.











53. The compound of any one of claims 43-52, wherein T^1 is CR^{T1}; and R^{T1} and R^{T2}, taken together with the intervening atoms, form an optionally substituted heteroaryl ring, such as pyrrole, imidazole, or 1,2,4-triazole.




54. The compound of any one of claims 43-52, wherein T^3 is CR^{T3}; and R^{T3} and R^{T2}, taken together with the intervening atoms, form an optionally substituted heteroaryl ring, such as pyrrole, imidazole, 1,2,4-triazole, or pyridine.

55. The compound of claim 43, selected from the following table:

.

56. A pharmaceutical composition, comprising a compound of any one of claims 1-55, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

57. Use of a compound of any one of claims 1-55, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease or condition characterized by aberrant complement system activity, wherein the disease or condition is an immunological disorder, a disease of the central nervous system, a neurodegenerative disease or neurological disease, a renal disease, a cardiovascular disease, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, catastrophic antiphospholipid syndrome, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), IgA nephropathy, age-related macular degeneration (AMD), systemic lupus erythematosus, warm autoimmune hemolytic anemia, or focal segmental glomerulosclerosis.

58. The use of claim 57, wherein the disease or condition characterized by aberrant complement system activity is an immunological disorder.

59. The use of claim 57, wherein the disease or condition characterized by aberrant complement system activity is a disease of the central nervous system.

60. The use of claim 57, wherein the disease or condition characterized by aberrant complement system activity is a neurodegenerative disease or neurological disease.

61. The use of claim 57, wherein the disease or condition characterized by aberrant complement system activity is a renal disease.

62. The use of claim 57, wherein the disease or condition characterized by aberrant complement system activity is a cardiovascular disease.

63. The use of claim 57, wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, catastrophic antiphospholipid syndrome, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), IgA nephropathy, age-related macular degeneration (AMD), systemic lupus erythematosus, warm autoimmune hemolytic anemia, and focal segmental glomerulosclerosis.

64. The use of claim 57, wherein the disease or condition characterized by aberrant complement system activity is paroxysmal nocturnal hemoglobinuria.

65. A compound of any one of claims 1-55, or a pharmaceutically acceptable salt thereof, for use in therapy.